UPDATE | Studies show that after around 6 months, antibodies from Sinovac's COVID-19 injection wane, although a booster can assist.
According to a lab research done in Beijing, antibodies generated by Sinovac Biotech's (SVA.O) COVID-19 vaccine fall below a critical threshold six months after a second dosage for most patients, however a third injection might have a substantial boosting impact.
In an unpeer reviewed publication released on Sunday, Chinese researchers revealed the results of a study of blood samples from healthy people aged 18 to 59.
Only 16.9% and 35.2 percent of patients who received two doses two or four weeks apart had levels of neutralising antibodies over the threshold six months following the second dosage, according to the study.
Those figures were based on data from two cohorts of more than 50 individuals each, with a total of 540 people taking part in the study.
The study found that when individuals in certain cohorts were given a third dosage approximately six months after the second, neutralising antibody levels had grown around 3-5 times from four weeks after the second dose after a further 28 days.
Researchers from Jiangsu province's disease control agencies, Sinovac, and other Chinese institutes collaborated on the study.
Researchers cautioned the study did not test the antibodies' effect against more transmissible variants, and that further research was needed to assess antibody duration after a third shot.
Comments
Post a Comment